F18-氟脱氧葡萄糖正电子发射断层显像/磁共振成像在乳腺癌分期/再分期中的表现:综述与荟萃分析
该系统综述与荟萃分析检索PubMed至2018年1月29日,纳入8项研究评估F18-FDG PET/MRI在乳腺癌分期/再分期中的诊断性能。基于患者的汇总敏感度0.98、特异度0.87、AUC 0.99;基于病灶的汇总敏感度0.91、特异度0.95、AUC 0.99。作者结论认为F18-FDG PET/MRI在乳腺癌分期/再分期中具有优异的诊断性能,应考虑用于乳腺癌患者分期。
要点
- 基于患者分析:汇总敏感度0.98(95%CI 0.95-0.99),特异度0.87(95%CI 0.76-0.95),AUC 0.99。
- 基于病灶分析:汇总敏感度0.91(95%CI 0.88-0.94),特异度0.95(95%CI 0.92-0.97),AUC 0.99。
- 作者结论认为F18-FDG PET/MRI在乳腺癌分期/再分期中诊断性能优异,应考虑用于分期。
核心结论
- F18-FDG PET/MRI在乳腺癌患者分期/再分期中具有优异的诊断性能,作者认为应考虑用于乳腺癌患者的分期。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed数据库自建库至2018年1月29日,纳入8项报告F18-FDG PET/MRI乳腺癌分期性能的研究。
诊断标准与关键数值
- 基于患者分析:汇总敏感度0.98(95%CI 0.95-0.99),特异度0.87(95%CI 0.76-0.95),PLR 4.59(95%CI 1.91-11.05),NLR 0.03(95%CI 0.01-0.09),DOR 203.07(95%CI 50.33-819.38),AUC 0.99,Q*指数0.96。
- 基于病灶分析:汇总敏感度0.91(95%CI 0.88-0.94),特异度0.95(95%CI 0.92-0.97),PLR 11.28(95%CI 4.25-29.96),NLR 0.07(95%CI 0.02-0.22),DOR 286.46(95%CI 64.15-1279.17),AUC 0.99,Q*指数0.95。
临床应用与阅片要点
- 作者结论认为F18-FDG PET/MRI在乳腺癌分期/再分期中诊断性能优异,应考虑用于乳腺癌患者分期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This systematic review and meta-analysis was performed to assess the staging/restaging performance of F18-fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in breast cancer.
METHODS: A comprehensive search was performed in PubMed databases for studies reporting the staging performance of F18-FDG PET/MRI in breast cancer from the inception of these databases to January 29, 2018. Eight studies were included in this systematic review and meta-analysis. Pooled estimates of patient- and lesion-based sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) of F18-FDG PET/MRI were calculated alongside 95% confidence intervals (CIs). A summary receiver operating characteristic curve (SROC) was plotted and the area under the SROC curve (AUC) was determined alongside the Q* index.
RESULTS: The patient-based overall pooled sensitivity, specificity, PLR, NLR, DOR, and AUC of F18-FDG PET/MRI for staging in breast cancer were 0.98 (95% CI, 0.95-0.99), 0.87 (95% CI, 0.76-0.95), 4.59 (95% CI, 1.91-11.05), 0.03 (95% CI, 0.01-0.09), 203.07 (95% CI, 50.33-819.38), and 0.99, respectively. The lesion-based overall pooled sensitivity, specificity, PLR, NLR, DOR, and AUC of F18-FDG PET/MRI for staging in breast cancer were 0.91 (95% CI, 0.88-0.94), 0.95 (95% CI, 0.92-0.97), 11.28 (95% CI, 4.25-29.96), 0.07 (95% CI, 0.02-0.22), 286.46 (95% CI, 64.15-1279.17), and 0.99, respectively. The overall diagnostic accuracies (Q* index) of the staging performance of F18-FDG PET/MRI in breast cancer were 0.96 (patient-based analysis) and 0.95 (lesion-based analysis).
CONCLUSION: F18-FDG PET/MRI has excellent diagnostic staging/restaging performance in patients with breast cancer, and thus should be considered for staging of patients with breast cancer.
引用
- Lin CY, Lin CL, Kao CH, et al. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis. Eur J Radiol. 2018. PMID: 30292261. doi:10.1016/j.ejrad.2018.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。